

Valsamo Anagnostou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145726/publications.pdf>

Version: 2024-02-01

54
papers

8,883
citations

126907

33
h-index

206112

48
g-index

57
all docs

57
docs citations

57
times ranked

15221
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in antigen presentation and cancer immunotherapy. <i>Immunity</i> , 2022, 55, 3-6.	14.3	5
2	An Evaluation of Pretrained BERT Models for Comparing Semantic Similarity Across Unstructured Clinical Trial Texts. <i>Studies in Health Technology and Informatics</i> , 2022, 289, 18-21.	0.3	4
3	Protocol of DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	1.9	9
4	Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3) in resectable gastric cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 321-321.	1.6	5
5	Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets. <i>Clinical Cancer Research</i> , 2022, 28, 2361-2372.	7.0	2
6	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, e004688.		34
7	Multicenter phase II study of abemaciclib and ramucirumab in metastatic esophageal/gastroesophageal junction carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4169-TPS4169.	1.6	0
8	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—a phase 3 randomized trial. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8599-TPS8599.	1.6	0
9	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
10	The status of tumor mutational burden and immunotherapy. <i>Nature Cancer</i> , 2022, 3, 652-656.	13.2	48
11	Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.3	0
12	Translating noninvasive molecular responses into clinical reality for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 65-66.	27.6	9
13	Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 4042-4042.	1.6	0
14	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	27.8	234
15	Detection and characterization of lung cancer using cell-free DNA fragmentomes. <i>Nature Communications</i> , 2021, 12, 5060.	12.8	161
16	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PRE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920.	30.7	62
17	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 99-111.	13.2	141
18	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , 2020, 1, 100139.	6.5	45

#	ARTICLE	IF	CITATIONS
19	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	16.8	203
20	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
21	High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets. <i>Cancer Immunology Research</i> , 2020, 8, 396-408.	3.4	103
22	Visual storytelling enhances knowledge dissemination in biomedical science. <i>Journal of Biomedical Informatics</i> , 2020, 107, 103458.	4.3	14
23	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	12.8	158
24	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	7.0	90
25	Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9525-9525.	1.6	1
26	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
27	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
28	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213.	0.9	75
29	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
30	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	8.2	100
31	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	27.0	1,495
32	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	1.8	129
33	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	80
34	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 888-899.	3.4	118
35	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	9.4	706
36	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	7.0	115

#	ARTICLE	IF	CITATIONS
37	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	808
38	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	28.9	366
39	Primary parotid adenocarcinoma metastasis to the spleen with mutation: cytological findings and review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 5999-6005.	0.5	2
40	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	12.8	393
41	Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Science Translational Medicine</i> , 2015, 7, 283ra53.	12.4	347
42	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	27.8	398
43	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. <i>Laboratory Investigation</i> , 2015, 95, 334-341.	3.7	52
44	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. <i>Laboratory Investigation</i> , 2014, 94, 467-474.	3.7	48
45	Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1436-1442.	3.8	41
46	Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e31331.	2.5	55
47	Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non-Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2011, 179, 580-589.	3.8	21
48	Antibody validation. <i>BioTechniques</i> , 2010, 48, 197-209.	1.8	548
49	Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution. <i>Applied Clinical Informatics</i> , 2010, 01, 38-49.	1.7	6
50	Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 77-85.	2.5	45
51	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. <i>Nature</i> , 2009, 459, 1085-1090.	27.8	311
52	Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. <i>Anticancer Research</i> , 2008, 28, 1411-5.	1.1	11
53	Epithelioid haemangioendothelioma of the lung presenting with pulmonary nocardiosis. <i>In Vivo</i> , 2007, 21, 1123-6.	1.3	4
54	Ontogeny of intrinsic innervation in the human kidney. <i>Anatomy and Embryology</i> , 2004, 209, 41-47.	1.5	17